Evidence suggests that PPARα and PPARβ/δ are potential therapeutic targets to prevent obesity,496 while PPARγ, a master regulator of adipogenesis, modulates obesity-related phenotypes.497. Here, PPARA is linked to obesity due to melanocortin 4 receptor deficiency.